4c3e: Difference between revisions
No edit summary |
No edit summary |
||
Line 1: | Line 1: | ||
==HRSV M2-1 mutant S58D S61D, P21 crystal== | ==HRSV M2-1 mutant S58D S61D, P21 crystal== | ||
<StructureSection load='4c3e' size='340' side='right' caption='[[4c3e]], [[Resolution|resolution]] 2.40Å' scene=''> | <StructureSection load='4c3e' size='340' side='right' caption='[[4c3e]], [[Resolution|resolution]] 2.40Å' scene=''> | ||
Line 5: | Line 6: | ||
</td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | </td></tr><tr id='ligand'><td class="sblockLbl"><b>[[Ligand|Ligands:]]</b></td><td class="sblockDat"><scene name='pdbligand=ZN:ZINC+ION'>ZN</scene></td></tr> | ||
<tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4c3b|4c3b]], [[4c3d|4c3d]]</td></tr> | <tr id='related'><td class="sblockLbl"><b>[[Related_structure|Related:]]</b></td><td class="sblockDat">[[4c3b|4c3b]], [[4c3d|4c3d]]</td></tr> | ||
<tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4c3e FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4c3e OCA], [http://www.rcsb.org/pdb/explore.do?structureId=4c3e RCSB], [http://www.ebi.ac.uk/pdbsum/4c3e PDBsum]</span></td></tr> | <tr id='resources'><td class="sblockLbl"><b>Resources:</b></td><td class="sblockDat"><span class='plainlinks'>[http://oca.weizmann.ac.il/oca-docs/fgij/fg.htm?mol=4c3e FirstGlance], [http://oca.weizmann.ac.il/oca-bin/ocaids?id=4c3e OCA], [http://pdbe.org/4c3e PDBe], [http://www.rcsb.org/pdb/explore.do?structureId=4c3e RCSB], [http://www.ebi.ac.uk/pdbsum/4c3e PDBsum], [http://prosat.h-its.org/prosat/prosatexe?pdbcode=4c3e ProSAT]</span></td></tr> | ||
</table> | </table> | ||
== Function == | == Function == | ||
Line 17: | Line 18: | ||
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.<br> | ||
</div> | </div> | ||
<div class="pdbe-citations 4c3e" style="background-color:#fffaf0;"></div> | |||
==See Also== | ==See Also== |
Revision as of 13:54, 5 August 2016
HRSV M2-1 mutant S58D S61D, P21 crystalHRSV M2-1 mutant S58D S61D, P21 crystal
Structural highlights
Function[M21_HRSVA] Acts as a transcriptional elongation factor to prevent premature termination during transcription thus allowing complete synthesis of RSV mRNAs. Functions also as a processivity and antitermination factor to permit transit of the polymerase through intergenic regions to access promoter distal genes. Plays a role in the association of the matrix protein with the nucleocapsid, which initiates assembly and budding. Also, can activate NF-kappa-B through association with host RELA.[1] [2] [3] Publication Abstract from PubMedThe M2-1 protein of the important pathogen human respiratory syncytial virus is a zinc-binding transcription antiterminator that is essential for viral gene expression. We present the crystal structure of full-length M2-1 protein in its native tetrameric form at a resolution of 2.5 A. The structure reveals that M2-1 forms a disk-like assembly with tetramerization driven by a long helix forming a four-helix bundle at its center, further stabilized by contact between the zinc-binding domain and adjacent protomers. The tetramerization helix is linked to a core domain responsible for RNA binding activity by a flexible region on which lie two functionally critical serine residues that are phosphorylated during infection. The crystal structure of a phosphomimetic M2-1 variant revealed altered charge density surrounding this flexible region although its position was unaffected. Structure-guided mutagenesis identified residues that contributed to RNA binding and antitermination activity, revealing a strong correlation between these two activities, and further defining the role of phosphorylation in M2-1 antitermination activity. The data we present here identify surfaces critical for M2-1 function that may be targeted by antiviral compounds. Crystal structure of the essential transcription antiterminator M2-1 protein of human respiratory syncytial virus and implications of its phosphorylation.,Tanner SJ, Ariza A, Richard CA, Kyle HF, Dods RL, Blondot ML, Wu W, Trincao J, Trinh CH, Hiscox JA, Carroll MW, Silman NJ, Eleouet JF, Edwards TA, Barr JN Proc Natl Acad Sci U S A. 2014 Jan 16. PMID:24434552[4] From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine. See AlsoReferences
|
|